Lung cancer: Early events, early interventions conference summary for the 46th annual Thomas L. Petty aspen lung conference

Chest

Volumn 125, Issue 5 SUPPL., 2004, Pages 167S-172S

  Carbone, David P ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GEFITINIB; GLUCOCORTICOID; ILOPROST; NONSTEROID ANTIINFLAMMATORY AGENT; PEMETREXED; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RETINOL;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 2442608357     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Schwartz AG, Rothrock M, Yang P, et al. Increased cancer risk among relatives of nonsmoking lung cancer cases. Genet Epidemiol 1999; 17:1-15
2. Witschi H, Espiritu I, Dance ST, et al. A mouse lung tumor model of tobacco smoke carcinogenesis. Toxicol Sci 2002; 68:322-330
3. Witschi H. Successful and not so successful chemoprevention of tobacco smoke-induced lung tumors. Exp Lung Res 2000; 26:743-755
4. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults N Engl J Med 2003; 348:1625-1638
5. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990; 5:1603-1610
6. Wolf P, Hu YC, Doffek K, et al. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001; 61:8113-8117
7. Banerjee AK, Rabbitts PH, George J. Lung cancer: 3. Fluorescence bronchoscopy; clinical dilemmas and research opportunities. Thorax 2003; 58:266-271
8. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002; 62: 2370-2377
9. Massion PP, Kuo WL, Stokoe D, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002; 62:3636-3640
10. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003; 226:756-761
11. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88:1560-1570
12. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996; 88:1550-1559
13. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003; 111:727-735
14. Keith RL, Miller YE, Hoshikawa Y, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002; 62:734-740